A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Intellia Therapeutics, Inc. NTLA

Weak (early) Health Tech sector · Intellia — CRISPR gene-editing therapies, still clinical-stage and pre-revenue.

Key quality signals

Revenue growth (YoY)45%

Gross margin-31.9%

Gross profits / assets-0.03

Rule of 40-591.6

Net margin-636.6%

Cash runway (months)12.4

PEG—

P/S21.9

Risk flags

Burning cash — operating margin is negative.Thin gross margin — keeps little of each sales dollar (judge it against its industry).Heavy dilution (~15%/yr) — top-decile share issuers have historically underperformed.Parabolic one-day spike (+13%) in the last month — extreme single-day moves tend to mean-revert.News: possible dilution — a share offering or raise is on the tape.

Positive signals

Growth accelerating — revenue growth sped up ~58 points year-on-year; acceleration is an early fundamental tell (annual data, so it's coarse).

Insider & analyst context

Analyst mix: 5 strong-buy / 10 buy / 11 hold / 2 sell. Ratings are context, not a price target.

Similar Health Tech names

Intuitive Surgical, Inc.DexCom, Inc.Veeva Systems Inc.CRISPR Therapeutics AGTempus AI, Inc.

← All Health Tech names · Open NTLA in the interactive screener →

Data as of 2026-06-09 22:43 (end-of-day). How grades are computed →